Cao Maize C, Chancellor Andrew, Charleston Alison, Dragunow Mike, Scotter Emma L
a Department of Pharmacology and Centre for Brain Research , University of Auckland , Auckland , New Zealand.
b Tauranga Hospital , Tauranga , New Zealand , and.
Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):285-293. doi: 10.1080/21678421.2018.1432660. Epub 2018 Jan 30.
We determined the mortality rates of motor neuron disease (MND) in New Zealand over 22 years from 1992 to 2013. Previous studies have found an unusually high and/or increasing incidence of MND in certain regions of New Zealand; however, no studies have examined MND rates nationwide to corroborate this.
Death certificate data coded G12.2 by International Classification of Diseases (ICD)-10 coding, or 335.2 by ICD-9 coding were obtained. These codes specify amyotrophic lateral sclerosis, progressive bulbar palsy, or other motor neuron diseases as the underlying cause of death. Mortality rates for MND deaths in New Zealand were age-standardized to the European Standard Population and compared with rates from international studies that also examined death certificate data and were age-standardized to the same standard population.
The age-standardized mortality from MND in New Zealand was 2.3 per 100,000 per year from 1992-2007 and 2.8 per 100,000 per year from 2008-2013. These rates were 3.3 and 4.0 per 100,000 per year, respectively, for the population 20 years and older. The increase in rate between these two time periods was likely due to changes in MND death coding from 2008. Contrary to a previous regional study of MND incidence, nationwide mortality rates did not increase steadily over this time period once aging was accounted for. However, New Zealand MND mortality rate was higher than comparable studies we examined internationally (mean 1.67 per 100,000 per year), suggesting that further analysis of MND burden in New Zealand is warranted.
我们确定了1992年至2013年这22年间新西兰运动神经元病(MND)的死亡率。先前的研究发现新西兰某些地区MND的发病率异常高和/或呈上升趋势;然而,尚无研究在全国范围内对MND发病率进行调查以证实这一点。
获取了国际疾病分类(ICD)-10编码为G12.2或ICD-9编码为335.2的死亡证明数据。这些编码将肌萎缩侧索硬化、进行性延髓麻痹或其他运动神经元病指定为潜在死因。新西兰MND死亡的死亡率按照欧洲标准人口进行年龄标准化,并与其他同样检查了死亡证明数据且按照相同标准人口进行年龄标准化的国际研究的死亡率进行比较。
1992 - 2007年新西兰MND的年龄标准化死亡率为每年每10万人2.3例,2008 - 2013年为每年每10万人2.8例。对于20岁及以上人群,这两个时期的死亡率分别为每年每10万人3.3例和4.0例。这两个时间段之间的死亡率上升可能是由于2008年MND死亡编码的变化。与之前关于MND发病率的区域研究相反,在考虑年龄因素后,这一时期全国范围内的死亡率并未稳步上升。然而,新西兰的MND死亡率高于我们在国际上考察的可比研究(平均每年每10万人1.67例),这表明有必要对新西兰的MND负担进行进一步分析。